ANCA Vasculitis Drug Market

研究執行與發布：Coherent Market Insights　·　發布日期 2026-03-20　·　152 頁
由量子訊息有限公司（Quantum Information）在台灣代理銷售與提供授權諮詢。

2026 年市場規模: USD 574.9 Mn
2033 年預估規模: USD 836.3 Mn
年複合成長率 CAGR: 5.5%

以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。

出版商 Coherent Market Insights 產業別 Healthcare & Life Sciences出版日期 2026-03-20頁數 152報告編號 CMI5154

授權報價

Single User Price	$4,500 USD
Enterprise License	$10,000 USD

洽詢購買申請 Sample

完整報告名稱與涵蓋範圍

ANCA Vasculitis Drug Market, By Type (Granulomatosis with Polyangiitis (GPA), Microscopic Polyangiitis (MPA), Eosinophilic Granulomatosis with Polyangiitis (EGPA), Renal-limited Vasculitis), By Drug Type (Glucocorticoids, Cyclophosphamide, Rituximab, Methotrexate, Mycophenolate mofetil, Azathioprine, Mepolizumab, Avacopan, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

報告摘要

Anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) is a group of autoimmune diseases characterized by inflammation and damage to small blood vessels. Self-reactive antibodies known as ANCAs, which bind to and excessively activate neutrophils, are the cause behind this inflammation. This immune system malfunction is caused by hereditary and environmental factors. ANCA vasculitis can result in a variety of symptoms depending on the organ or body part affected. For instance, if the skin's blood vessels are harmed, a rash may result. Blood and protein leakage into the urine as well as kidney damage can result from problems with the blood vessels in the kidney. There are three main types of ANCA vasculitis, microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA), and eosinophilic granulomatosis with polyangiitis (EGPA). Currently, there is no cure for the disease and treatments are available to manage the condition. Patients normally undergo two phases of treatment, one designed to induce the remission of symptoms (induction treatment), and a second phase meant to keep patients in remission for as long as possible (maintenance treatment). Market Dynamics Key players in market are focused on carrying out research and development activities and demonstrating the results of the studies at various medical conferences, which is expected to drive the market growth over the forecast period. For instance, in May 2022, ChemoCentryx, Inc., a biopharmaceutical company, announced upcoming presentations at three key medical conferences that would highlight findings from the pivotal Phase III ADVOCATE trial that supported the approval of tavneos (avacopan), an orally administered selective complement 5a receptor (C5aR) inhibitor, and research into the burden of glucocorticoid use in ANCA-associated vasculitis. The three conferences were ATS 2022 (American Thoracic Society), May 15-17, 2022, San Francisco, ISPOR 2022 (International Society for Pharmacoeconomics and Outcomes Research), May 15-18, 2022, Washington, and 59th ERA Conference (European Renal Association), May 19-22, 2022, Paris, France/Virtual Key features of the study • This report provides in-depth analysis of the global ANCA vasculitis drug market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players • It profiles key players in the global ANCA vasculitis drug market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies • Key companies covered as a part of this study include ChemoCentryx, Inc., Vifor Pharma, GlaxoSmithKline plc, Amgen, Genentech, Inc., Pfizer Inc., Biogen, InflaRx GmbH, and AstraZeneca • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics • The global ANCA vasculitis drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global ANCA vasculitis drug market Market Segmentation • Global ANCA Vasculitis Drug Market, By Type o Granulomatosis with Polyangiitis (GPA) o Microscopic Polyangiitis (MPA) o Eosinophilic Granulomatosis with Polyangiitis (EGPA) o Renal-limited Vasculitis • Global ANCA Vasculitis Drug Market, By Drug Type o Glucocorticoids o Cyclophosphamide o Rituximab o Methotrexate o Mycophenolate mofetil o Azathioprine o Mepolizumab o Avacopan o Others • Global ANCA Vasculitis Drug Market, By Distribution Channel o Hospital Pharmacies o Retail Pharmacies o Online Pharmacies • Global ANCA Vasculitis Drug Market, By Region o North America  U.S.  Canada o Latin America  Brazil  Argentina  Mexico  Rest of Latin America o Europe  Germany  U.K.  Spain  France  Italy  Russia  Rest of Europe o Asia Pacific  China  India  Japan  Australia  South Korea  ASEAN  Rest of Asia Pacific o Middle East & Africa  GCC Countries  Israel  Rest of Middle East & Africa • Key Players o ChemoCentryx, Inc. o Vifor Pharma o GlaxoSmithKline plc o Amgen o Genentech, Inc. o Pfizer Inc. o Biogen o InflaRx GmbH o AstraZeneca.

目錄 Table of Contents

Table of Contents 1. Research Objectives and Assumptions o Research Objectives o Assumptions o Abbreviations 2. Market Purview o Report Description  Market Definition and Scope o Executive Summary  Market Snapshot, By Type  Market Snapshot, By Drug Type  Market Snapshot, By Distribution Channel  Market Snapshot, By Country o Coherent Opportunity Map (COM) 3. Market Dynamics, Regulations, and Trends Analysis o Market Dynamics  Drivers  Restraints  Market Opportunities o Impact Analysis o Market Trends o Key Developments o Regulatory Scenario o PEST Analysis o Epidemiology o Product Launch/Approvals 4. Global ANCA Vasculitis Drug Market, By Type, 2026 – 2033, (USD Mn) o Overview  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2026 – 2033  Segment Trends o Granulomatosis with Polyangiitis (GPA)  Overview  Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Mn) o Microscopic Polyangiitis (MPA)  Overview  Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Mn) o Eosinophilic Granulomatosis with Polyangiitis (EGPA)  Overview  Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Mn) o Renal-limited Vasculitis  Overview  Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Mn) 5. Global ANCA Vasculitis Drug Market, By Drug Type, 2026 – 2033, (USD Mn) o Overview  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2026 – 2033  Segment Trends o Glucocorticoids  Overview  Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Mn) o Cyclophosphamide  Overview  Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Mn) o Rituximab  Overview  Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Mn) o Methotrexate  Overview  Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Mn) o Mycophenolate mofetil  Overview  Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Mn) o Azathioprine  Overview  Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Mn) o Mepolizumab  Overview  Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Mn) o Avacopan  Overview  Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Mn) o Others  Overview  Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Mn) 6. Global ANCA Vasculitis Drug Market, By Distribution Channel, 2026 – 2033, (USD Mn) o Overview  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2026 – 2033  Segment Trends o Hospital Pharmacies  Overview  Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Mn) o Retail Pharmacies  Overview  Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Mn) o Online Pharmacies  Overview  Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Mn) 7. Global ANCA Vasculitis Drug Market, By Region, 2026 – 2033, (USD Mn) o Introduction  Market Share Analysis, By Region, 2026 and 2033 (%)  Y-o-Y Growth Analysis, For Regions, 2026–2033  Regional Trends o North America  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 – 2033, (USD Mn) o U.S. o Canada o Latin America  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 – 2033, (USD Mn) o Brazil o Mexico o Argentina o Rest of Latin America o Europe  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 – 2033, (USD Mn) o UK o Germany o Italy o France o Spain o Russia o Rest of Europe o Asia Pacific  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 – 2033, (USD Mn) o China o India o Japan o ASEAN o Australia o South Korea o Rest of Asia Pacific o Middle East  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 – 2033, (USD Mn) o GCC o Israel o Rest of Middle East o Africa  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2026 – 2033, (USD Mn) o North Africa o Central Africa o South Africa 8. Competitive Landscape o ChemoCentryx, Inc.  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Vifor Pharma  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o GlaxoSmithKline plc  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Amgen  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Genentech, Inc.  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Pfizer Inc.  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Biogen  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o InflaRx GmbH  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o AstraZeneca  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies 9. Section o Research Methodology o About Us

提及公司

ChemoCentryx, Inc.Vifor PharmaGlaxoSmithKline plcAmgenGenentech, Inc.Pfizer Inc.BiogenInflaRx GmbHAstraZeneca.

同分類最新報告（醫療與生命科學）

常見問題

這份報告可以先索取樣本嗎？

可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。

報告價格如何計算？

報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。

下單後多久交付？如何付款？

一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。

量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・聯絡我們